ArticleFrontiers in chemistry2026
Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To clarify atorvastatin's role in diabetic peripheral neuropathy (DPN) amid its controversial neuroprotective and neurotoxic effects. Methods: Integrated network toxicology, single-cell RNA sequencing (scRNA-seq), molecular docking, molecular dynamics simulations, and Results: Network toxicology identified TNF, CTNNB1, CASP3 as core targets (TNF as key hub), enriched in DPN-related pathways (oxidative stress, inflammation). scRNA-seq suggested that these targets are expressed in sensory neuron populations. Molecular docking and molecular dynamics simulations suggested that atorvastatin can interact with the selected targets, with relatively favorable predicted affinity for TNFα. Conclusion: Our findings are consistent with a potential involvement of TNF/TNFα-associated inflammatory responses in atorvastatin-related cellular injury under the tested
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.